How can one optimally design a clinical trial program for a medical device for a FDA clearance/approval submission? OneMedRadio spoke with Dr. Vladimir Dragalin and Dr. Michael Feldstein of Aptiv Solutions to discuss the changing tides of medical device regulatory and the advantages of using an adaptive design trial.
OneMedForum NY 2012 was well received and the turnout met and exceeded expectations. Unlike the past several years, there is a higher level of optimism within the investment community, according to attendees. The crux of this optimism, of course, is the perceived greater flow of capital to microcap companies that the JOBS Act can provide.
Christine Jacobs, CEO of Theragenics, enlightened OneMedForum NY 2012 attendees on a categorical operational observation: while the number of employees represent a fair barometer of her company’s success, they also define her compliance costs. Jacobs and David Weild, former NASDAQ Vice Chair, discussed the evolving market landscape with the passing of the JOBS Act.
Epion Health announces a partnership with CaerVision to deploy tablets at the point of care. CaerVision has allocated $3.5 million dollars to this initiative.
BIO (Biotechnology Industry Organization) and OneMedPlace share many of the same goals. Both groups want to see innovative and effective life science therapies come to the marketplace.
OneMedPlace has announced that Christine Jacobs, Co-Chair to the SEC Advisory Board on Small and Emerging companies, will discuss efforts by the SEC to address the challenges faced by small public companies.
BiognoSYS, a Swiss leader and founder of proteomics in the Greater Zurich Area, is developing targeted proteomics based on a novel mass spectrometric technology.
OneMedForum NY 2012 to be held tomorrow, July 12 stands to be a huge success. The third annual OneMedForum NY opens with a reception on […]
The Securities and Exchange Commission missed a deadline of July 4, 2012 to adopt rules lifting a general advertising ban for private securities offerings as a part of the JOBs Act.
Delenex Therapeutics, a Swiss biotech in the Greater Zurich Area is developing antibodies to treat serious medical conditions with high unmet need.
Copyright © 2025 | WordPress Theme by MH Themes